Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China

Xun Li[a], Luwen Wang[a], Shaonan Yan[a], Fan Yang[a], Longkui Xiang[a], Jiling Zhu[a], Bo Shen[b,**], Zuojiong Gong[a,*]

[a] Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China
[b] Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China

ABSTRACT

Objectives: This study aims to summarize the clinical characteristics of death cases with COVID-19 and to identify critically ill patients of COVID-19 early and reduce their mortality.

Methods: The clinical records, laboratory findings and radiological assessments included chest X-ray or computed tomography were extracted from electronic medical records of 25 died patients with COVID-19 in Renmin Hospital of Wuhan University from Jan 14 to Feb 13, 2020. Two experienced clinicians reviewed and abstracted the data.

Results: The age and underlying diseases (hypertension, diabetes, etc.) were the most important risk factors for death of COVID-19 pneumonia. Bacterial infections may play an important role in promoting the death of patients. Malnutrition was common to severe patients. Multiple organ dysfunction can be observed, the most common organ damage was lung, followed by heart, kidney and liver. The rising of neutrophils, SAA, PCT, CRP, cTnI, D-dimer, LDH and lactate levels can be used as indicators of disease progression, as well as the decline of lymphocytes counts.

Conclusions: The clinical characteristics of 25 death cases with COVID-19 we summarized, which would be helpful to identify critically ill patients of COVID-19 early and reduce their mortality.

© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

The pneumonia caused by the 2019 novel coronavirus (SARS-CoV-2) is a highly infectious disease, which was occurred in Wuhan, Hubei Province, China in December 2019 (Zhu et al., 2019). It is reported that the person-to-person transmission in hospital and family settings has been accumulating (Chan et al., 2020; Phan et al., 2020; Wang et al., 2020). The patients' common clinical manifestations included fever, nonproductive cough, dyspnea, myalgia, fatigue, normal or decreased leukocyte counts, and radiographic evidence of pneumonia (Huang et al., 2020). Chen et al. reported that mortality of COVID-19 was 4.3%, and severe cases (treated in the ICU) were older, more likely to have underlying comorbidities, dyspnea and anorexia (Wang et al., 2020). As

of February 13, 2020, a total of 55,748 cases of COVID-19 in China have been confirmed and 1380 patients have died from the disease (Qiu et al., 2017). However, the clinical characteristics of the dyed patients were still not clearly clarified. In this study, we summarized the clinical characteristics of 25 death cases with COVID-19, the purpose is to identify critically ill patients of COVID-19 early and reduce their mortality.

Methods

Study design and patients

We performed a retrospective review of medical records from 25 death cases with COVID-19 in Renmin Hospital of Wuhan University from Jan 14 to Feb 13, 2020. All 25 dead patients with COVID-19 tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by use of RT-PCR on samples from there respiratory tract. Diagnosis of COVID-19 was based on the WHO's interim guidelines (NHC, 2020). This study was reviewed and approved by the Medical Ethical Committee of Renmin Hospital of Wuhan University.

* Corresponding author at: Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China.
** Corresponding author at: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
E-mail addresses: 574190062@qq.com (B. Shen), zjgong@163.com (Z. Gong).

Data collection

The clinical symptoms and signs, laboratory findings and radiologic assessments included chest X-ray or computed tomography were extracted from electronic medical records. Two experienced clinicians reviewed and abstracted the data. Data were entered into a computerized database and cross-checked. The criteria for the confirmed-diagnosis of SARS-CoV-2 was that at least one gene site was amplified to be positive for nucleocapsid protein (NP) gene and open reading frame (ORF) 1ab gene. Two target genes, including NP and ORF1ab, were simultaneously amplified and tested during the real-time RT-PCR assay. Target 1 (NP): forward primer GGGGAACTTCTCCTGCTAGAAT; reverse primer CAGACATTTTGCTCTC AAGCTG; and the probe 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'. Target 2 (ORF1ab): forward primer CCCTGTGGGTTTTACACTTAA; reverse primer ACGATTGTGC ATCAGCTGA; and the probe 5'-VIC-CCGTCTGCGGTATGTGGAAAG GTTATGG-BHQ1-3'. The real-time RT-PCR assay was performed using a 2019-nCoV nucleic acid detection kit according to the manufacturer's protocol (Shanghai bio-germ Medical Technology Co Ltd). Specific primers and probes for SARS-CoV-2 RNA detection were based on the recommendation by the National Institute for Viral Disease Control and Prevention (China) (http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html).

Statistical analysis

Statistical analysis was done with SPSS, version 20.0. Continuous variables were directly expressed as median, and interquartile range (IQR) values. Categorical variables were expressed as number (%).

Results

General clinical characteristics

Of the 25 deaths, 10 were male and 15 were female. The median age of the dead was 73 years, range from 55 to100 years. The median course of the disease was 9 days, range from 4 to 20 days. All patients eventually died of respiratory failure and respirator was used in 23 patients (23/25, 92%). All (25/25, 100%) of those who died had underlying diseases, the most common of which was hypertension (16/25, 64%), followed by diabetes (10/25, 40%), heart diseases (8/25, 32%), kidney diseases (5/25, 20%), cerebral infarction (4/25, 16%), chronic obstructive pulmonary disease (COPD, 2/25, 8%), malignant tumors (2/25, 8%) and acute pancreatitis (1/25, 4%) (Table 1).

Analysis of laboratory test results of dead patients

In addition to the lung, the most common organ damage outside the lungs was the heart, (18 patients' serum hypersensitive troponin I (cTnI) or/and amino-terminal pro-brain natriuretic peptide (Pro-BNP) levels were increased (18/19, 94.7%)), followed by kidney (12 patients' serum blood urea nitrogen (BUN) or/and creatinine (Cr) levels were increased (12/25, 48%)) and liver (5 patients' serum alanine transaminase (ALT) and aspartate aminotransferase (AST) levels were increased (5/25, 20%)). Besides, all the patients' albumin and lactate levels were decreased and increased respectively. The routine blood test, procalcitonin (PCT), c-reactive protein (CRP) and serum amyloid A (SAA) were used to reflect changes of inflammatory response in COVID-19. In the patients' last test before death, white blood cell and neutrophil counts were elevated in 17 patients (17/25, 68%) and 18 patients (18/25, 72%), lymphocyte counts were decreased in 22 patients (22/25, 88%). Most patients had mild anemia, red blood cells and hemoglobin levels were decreased in 20 (20/25, 80%) and 17 (17/25, 68%) patients respectively. Most patients' PCT, CRP and SAA levels were elevated, the percentages were 90.5% (19/21), 95% (19/20) and 100% (21/21) respectively (Table 2).

Specific biomarker that indicating poor prognosis

In order to screen for biomarker indicating poor prognosis, we observed the changes of biochemical indicators in all patients (if repeated measurements were present). The results showed that

Table 1
General clinical characteristics of 25 death cases.

ID	Gender	Age	Course	Respirator	Underlying diseases
Patient1	F	55	17	Y	Diabetes
Patient2	M	62	11	Y	Diabetes, Hypertension
Patient3	F	81	17	Y	Hypertension, Heart disease
Patient4	F	72	10	Y	Diabetes, Hypertension, COPD, CRF, Heart disease
Patient5	F	83	7	Y	Diabetes, Hypertension, CRF, Heart disease
Patient6	M	70	8	Y	Hypertension
Patient7	M	73	9	Y	Heart disease
Patient8	F	74	8	Y	Heart disease
Patient9	M	82	7	Y	Hypertension, Heart disease
Patient10	M	78	10	Y	Hypertension, Hepatitis B
Patient11	F	78	9	Y	Hypertension
Patient12	F	67	7	Y	Diabetes
Patient13	M	94	14	Y	Hypertension
Patient14	F	69	13	Y	Heart disease
Patient15	M	90	9	Y	Hypertension, Cerebral infarction
Patient16	F	75	7	Y	Diabetes, Hypertension
Patient17	F	56	7	Y	Diabetes, Hypertension, Alimentary tract hemorrhage, Nephrotic syndrome
Patient18	F	59	11	Y	Diabetes, Hypertension
Patient19	M	56	17	Y	Diabetes, Hypertension, Cerebral infarction, NAFLD
Patient20	M	74	8	Y	Hypertension, Cerebral infarction
Patient21	F	55	10	N	Pulmonary nodules, after lobectomy
Patient22	F	64	20	N	lung cancer, chemotherapy
Patient23	F	74	19	Y	lymphoma, chemotherapy, interstitial pneumonia
Patient24	F	56	5	Y	Hypertension, acute pancreatitis, ureteral calculus, CRF
Patient25	M	100	4	Y	Heart disease, COPD, Diabetes, CRF

Table 2
Analysis of laboratory test results of dead patients

Laboratory findings	Test results (median, IQR)	Normal range	Total (n)	Below the Lower (n, %)	Above the Upper (n, %)
Alanine transaminase (U/L)	24 (16.5–46)	9–50	25	1 (4)	4 (16)
Aspartate aminotransferase (U/L)	37 (29.5–57.5)	15–40	25	0 (0)	9 (36)
Albumin (g/L)	32.81 (28.56–36.04)	40–55	25	25 (100)	0 (0)
Blood urea nitrogen (mmol/L)	9.29 (6.07–16.4)	3.6–9.5	23	2 (8.7)	10 (43.5)
Creatinine (μmol/L)	66 (49.5–161)	57–111	24	9 (37.5)	8 (33.3)
Hypersensitive troponin I (ng/mL)	316 (57–5420)	0–40	15	0 (0)	11 (73.3)
Amino-terminal pro-brain natriuretic peptide (pg/mL)	2450 (881–7992)	<75y: 0–125 >75y: 0–450	17	0 (0)	16 (94.1)
White blood cells (×10^9, cells/L)	11.01 (7.51–15.39)	3.5–9.5	25	3 (12)	17 (68)
Neutrophils (×10^9, cells/L)	10.41 (6.44–14.4)	1.8–6.3	25	0 (0)	18 (72)
Lymphocytes (×10^9, cells/L)	0.52 (0.27–0.71)	1.1–3.2	25	22 (88)	0 (0)
Red blood cells (×10^{12}, cells/L)	3.82 (3.07–4.13)	4.3–5.8	25	20 (80)	0 (0)
Hemoglobin (g/L)	121 (96–135.5)	130–175	25	17 (68)	0 (0)
Platelets (×10^9, cells/L)	150 (123–212)	125–350	25	7 (28)	0 (0)
Procalcitonin (ng/mL)	0.36 (0.13–1.91)	0–0.1	21	0 (0)	19 (90.5)
C-reactive protein (mg/L)	91.1 (55.55–146.3)	0–10	20	0 (0)	19 (95)
Serum amyloid A (mg/L)	300 (300–300)	0–10	21	0 (0)	21 (100)
Lactate (mmol/L)	3.35 (1.96–5.1)	0.5–1.5	16	0 (0)	16 (100)
SARS-CoV-2 virus	Positive	Negative	25	0 (0)	25 (100)

Below the Lower: Below the lower limit of normal range; Above the Upper: Above the upper limit of normal range.

the levels of the last test of neutrophils (14/16, 87.5%), PCT (11/11, 100%), CRP (11/13, 84.6%), cTnI (7/9, 77.8%), D-dimer (9/12, 75%), lactate dehydrogenase (LDH) (9/9, 100%) and lactate (12/12, 100%) were increased as compared to the first test, while the levels of lymphocytes were decreased (14/16, 87.5%). The SAA maintained a high level. Chest CT scan showed that the patients' pulmonary lesions were worse in the late stage than in the early stage (patient 3, patient 13 and patient 14) (Figure 1).


Figure 1. Chest CT scans of patient 3, patient 13 and patient 14.
A1: the early stage Chest CT scan of Patient 3; A2: the late stage Chest CT scan of Patient 3; B1: the early stage Chest CT scan of Patient 13; B2: the late stage Chest CT scan of Patient 13; C1: the early stage Chest CT scan of Patient 14; C2: the late stage Chest CT scan of Patient 14.

Table 3
Specific biomarker that indicating poor prognosis

Laboratory findings	The first test (median, IQR)	The last test (median, IQR)	Total (n)	Increased (n, %)	Decreased (n, %)
Neutrophils ($\times 10^9$, cells/L)	6.01 (3.09–8.90)	10.36 (2–17.31)	16	14 (87.5)	2 (12.5)
Lymphocytes ($\times 10^9$, cells/L)	0.62 (0.33–0.92)	0.40 (0.13–1.1)	16	12.5 (12.5)	14 (87.5)
Procalcitonin (ng/mL)	0.11 (0.07–0.24)	1.12 (0.14–1.98)	11	11 (100)	0 (0)
C-reactive protein (mg/L)	52.9 (19.55–79.8)	96.2 (53.35–161.1)	13	11 (84.6)	2 (15.4)
Serum amyloid A (mg/L)	300 (99.39–300)	300 (300–300)	12	5 (41.7)	1 (8.3)
Hypersensitive troponin I (pg/mL)	75 (37.5–258.5)	293 (167.5–1023)	9	7 (77.8)	1 (11.11)
D-dimer (mg/L)	1.18 (0.42–4.04)	9.93 (2.65–54.8)	12	9 (75)	3 (25)
Lactic dehydrogenase (U/L)	321 (250–372)	510 (364–617.5)	9	9 (100)	0 (0)
Lactate (mmol/L)	1.35 (0.68–1.5)	2.75 (1.83–3.55)	12	12 (100)	0 (0)

Increased, Decreased: Results of the last test vs. Results of the first test.

Discussion

In this study, we reported 25 death cases of with COVID-19. The clinical characters of these patients indicated that the age and underlying diseases were the most important risk factors for death. As concerning the underlying diseases, the most common one was hypertension, followed by diabetes, Heart disease, kidney disease, cerebral infarction, COPD, malignant tumors and acute pancreatitis (Table 3).

The SARS-CoV-2 has been identified as one of a class of single-stranded enveloped 39 RNA viruses, belonging to the beta-coronaviruses genus of the *Coronaviridae* family (Zhu et al., 2019). The analysis showed that both SARS-CoV-2 and the SARS-CoV shared a common ancestor that resembles the bat coronavirus HKU9-1 (Xu et al., 2020). And the severity of some cases with SARS-CoV-2 was similar to that of SARS-CoV (Chen et al., 2020). In the presents study, all the patients were died of respiratory failure, which indicated that the lung is the most common target organ of SARS-CoV-2.

Multiple organ dysfunction could also be observed, the most common organ damage outside the lungs was the heart, followed by kidney and liver. The results demonstrated that the death of the patient may be primarily related to impaired cardiopulmonary function. All the patients' albumin levels and 80% and 68% of patients' RBC and Hb levels were decreased, which indicates that malnutrition is common to severe patients.

COVID-19 is a viral disease characterized by normal or low white blood cell count and decreased lymphocyte count (National Health Commission of China, 2020). In this study, increased white blood cell and neutrophils count were observed in 68% and 72% of patients. In addition, PCT levels were elevated in 90.5% of patients. PCT is sensitive indicator of bacterial infection (Schuetz et al., 2017). The results indicated that bacterial infections may play an important role in promoting the death of patients.

CRP is a useful marker and gauge of inflammation, it plays an important role in host defense against invading pathogens as well as in inflammation (Wu et al., 2015). SAA is a plasma protein that transports lipids during inflammation (Frame et al., 2020). In the present study, CRP and SAA were elevated before death in 85% and 100% of patients, suggesting that there is a severe inflammatory cascade in patients with COVID-19.

In order to screen out biochemical indicators that are meaningful for the diagnosis of disease progression, we consulted the laboratory test results of all the dead patients, among which 16 patients had repeated measurements. The SAA maintained a high level in all the patients, this result indicated that elevated SAA levels are closely related to the poor prognosis of patients. The levels of the last test of neutrophils (87.5%), PCT (100%), CRP (84.6%), cTnI (77.8%), D-dimer (75%), LDH (100%) and lactate (100%) were increased as compared to the first test, while the levels of lymphocytes were decreased (87.5%), suggesting that the rising of neutrophils, PCT, CRP, cTnI, D-dimer, LDH and lactate levels can be used as indicators of disease progression, as well as the decline of lymphocytes counts.

This was a small sample size retrospective study, which was limited by the small numbers of patients and by using a retrospective method. In particular, some important laboratory results were incomplete.

In conclusion, the age and underlying diseases (hypertension, diabetes, etc.) is the most important risk factors for death of COVID-19. Bacterial infections may play an important role in promoting the death of patients. Malnutrition is common to severe patients. Multiple organ dysfunction can be observed, the most common organ damage outside the lungs is the heart, followed by kidney and liver. The rising of neutrophils, SAA, PCT, CRP, cTnI, D-dimer LDH and lactate levels can be used as indicators of disease progression, as well as the decline of lymphocytes counts.

Contributors

ZG and BS made substantial contributions to the study concept and design. XL was in charge of the manuscript draft. LW took responsibility for obtaining ethical approval and collecting samples. FY and JZ made substantial contributions to data acquisition, analysis and interpretation. SY and LX reviewed the data. ZG made substantial revisions to the manuscript.

Declaration of interests

We declare no competing interests.

References

Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;.

Frame NM, Kumanan M, Wales TE, Bandara A, Fandrich M, Straub JE, et al. Structural basis for lipid binding and function by an evolutionarily conserved protein, serum amyloid A. J Mol Biol 2020;.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;.

National Health Commission of China. New coronavirus pneumonia prevention and control program (4th ed.). 2020 http://www.gov.cn/zhengce/zhengceku/2020-01/28/5472673/fles/0f96c10cc09d4d36a6f9a9f0b42d972b.pdf (accessed 04.02.20; in Chinese).

National Health Commission of the People's Republic of China. Update on novel coronavirus-infected pneumonia situation as of 24:00 on February 13. 2020

http://www.nhc.gov.cn/xcs/yqfkdt/202002/553ff43ca29d4fe88f3837d49d6-b6ef1.shtml.

Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med 2020;.

Qiu S, Liu J, Xing F. 'Hints' in the killer protein gasdermin D: unveiling the secrets of gasdermins driving cell death. Cell Death Differ 2017;24:588–96.

Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017;10:D7498.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;.

Wu Y, Potempa LA, El KD, Filep JG. C-reactive protein and inflammation: conformational changes affect function. Biol Chem 2015;396:1181–97.

Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020;.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med 2019;2020.